short term TP is 2.95. Long term TP is 3.50. In the meantime, as stated above, I took profit yesterday and while the price will correct itself in the next day or two, I hope it will drop to 2.70 - 2.75, then only I will load again. Everything stock need a break in between, there is no such thing that everyday is up up up.
Today just a correction. It is normal to have correction to clear off the existing shareholder who wan to sell at current price. Once it is clear it will continue move up...
@ heaven123 , assuming annual share price have grow 15 percent per year, by end of 2022 it will become RM5.80, excluding dividend.
History has proven it, how much it is trading 5 years back? It was around 1.35. What is today price? 2.7x.. not rocket science but using 8th wonders of the world.
When I put comments 1 months ago...my comment were deleted. At that time, I said those who hold become long term investor, see if you have holding power.. you win.
@kakashit no worry, let the institutional funds sell.This is not the only instance!.If you were to follow other counters the same pattern and action can be dissected and inferred.Sometimes whether it is a mere coincidence or NOT.One local fund sells,another local fund will buy! I am aghast and puzzled with their investment decisions.Whether they have been properly guided by fundamentals,market moves,proper data analytics,financial analysis or the selling and buying just on emotions.If the latter,they sure to lose big time.Let them lose ,we prosper.Cheers:-)))
Will trend higher. The edge owner Thong has publicly bought YSP and was make known in the edge. This gem has been somehow exposed. More research house will begin to dig deeper into Ysp. Till then, happy investing.
YSP SAH ranks among the top KLCI-listed drug makers in Malaysia, by market cap (fourth-largest). ■ Its key customers are private GPs and hospitals, which contributed about 50% of total FY16 sales. The group also has a diversified product portfolio, including animal drugs. ■ Besides benefiting from rising local private healthcare spending, expansion into more underpenetrated and emerging markets are key earnings drivers moving forward. ■ Valuations are undemanding. The stock trades at 12.7x CY18F P/E. This is at a 28% discount to CIMB’s pharmaceutical sector historical 5-year mean P/E of 17.7x. ■ We initiate coverage on YSP SAH with an Add call and SOP-based TP of RM3.50.
believe me this YSPSAH is really one of the species that undervalue in BURSA but if u not believe better buy DUTCH LADY or NESTLE those were until when i dunno will hit its INTRISIC VALUE.
The INTRISIC VALUE of those DLADY & NESTLE were more than RM100 & you will only know if you know what the biz is...
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Thkent91
195 posts
Posted by Thkent91 > 2017-06-14 09:55 | Report Abuse
i am referring to paperplane comment,
TP 5 years RM6